Strategies for cellular immune therapy under investigation
Strategy . | Phase . | Relevant publications . |
---|---|---|
CD154 gene therapy | Phase 1 clinical trial | Biagi et al,30 Wierda et al31 |
Ex vivo T-cell activation | Phase 1 clinical trial | Kipps et al32 |
Heteroclytic peptide therapy | Preclinical phase | Trojan et al,33 Zirlik et al34 |
DC-based therapy | Phase 1 clinical trial | Hus et al35 |
CD20-HLA/CMV–targeting complexes | Preclinical phase | Kater et al,36 Mous et al37 |
Strategy . | Phase . | Relevant publications . |
---|---|---|
CD154 gene therapy | Phase 1 clinical trial | Biagi et al,30 Wierda et al31 |
Ex vivo T-cell activation | Phase 1 clinical trial | Kipps et al32 |
Heteroclytic peptide therapy | Preclinical phase | Trojan et al,33 Zirlik et al34 |
DC-based therapy | Phase 1 clinical trial | Hus et al35 |
CD20-HLA/CMV–targeting complexes | Preclinical phase | Kater et al,36 Mous et al37 |